COVID-19: Valneva plans to deliver its first vaccines to Europeans in the second quarter of 2022

The Franco-Austrian laboratory Valneva plans to deliver the first doses of its vaccine against Covid-19 in Europe in the second quarter of 2022, the company said in a press release published on Friday.

Valneva’s inactivated and adjuvanted vaccine against Covid, “VLA2001”, is currently being scrutinized by the Committee for Medicinal Products for Human Use (CHMP), which at the end of February sent the laboratory some additional questions regarding its serum.

“Valneva now expects to receive a positive recommendation from the CHMP for conditional authorization of VLA2001 for primary vaccination in adults aged 18-55 in April 2022,” the company said in a statement.

“After this conditional clearance, the company is expected to begin delivering planned doses of VLA2001 to European countries in the second quarter of 2022,” she said.

The laboratory indicates that it has signed an agreement with the European Commission “for the supply of a maximum of 60 million doses” over two years, including 24.3 in 2022.

Valneva has already received authorization for the emergency use of its vaccine from the Kingdom of Bahrain, which has purchased one million doses from it. These will start shipping in March.

On the other hand, the United Kingdom terminated in September a contract relating to 100 million doses of this candidate vaccine.

VLA2001 is “currently the only inactivated and adjuvanted vaccine candidate against COVID-19 in clinical development in Europe”, underlines Valneva.

Leave a Comment